Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23333048 | 0.88 | ACHE (0.55) | ACHESLC6A4CYP2D6OPRM1SLC22A1 | |
| SCHEMBL21770897 | 0.80 | TACR1 (0.53) | SLC6A4CYP2D6OPRM1SLC6A2SLC6A3 | |
| SCHEMBL11636242 | 0.78 | SLC6A2 (0.52) | ACHESLC6A4CYP2D6OPRM1SLC22A1 | |
| SCHEMBL6601890 | 0.76 | OPRD1 (0.63) | OPRM1OPRD1OPRK1 | |
| Profadol SCHEMBL160670 | 0.75 | ACHE (0.66) | ACHESLC6A4CYP2D6OPRM1SLC22A1 | |
| SCHEMBL7876407 | 0.75 | OPRM1 (0.46) | OPRM1OPRK1 | |
| SCHEMBL7876411 | 0.75 | OPRM1 (0.46) | OPRM1OPRK1 | |
| SCHEMBL7876410 | 0.75 | OPRM1 (0.46) | OPRM1OPRK1 | |
| Profadol SCHEMBL122313 | 0.74 | ACHE (0.64) | ACHESLC6A4CYP2D6OPRM1SLC22A1 | |
| SCHEMBL6654583 | 0.74 | DRD3 (0.66) | ACHEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | ACHE 3045/4885SLC6A4 1118/4885CYP2D6 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.